Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Lambda-1a vs Peginterferon Alfa-2a in Genotype 1 Hepatitis C
NCT01754974Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2013
- Primary completion
- Sep 2014
- Modality
- Cytokines & Interferons
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of peginterferon lambda-1a in hepatitis C (HCV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of subjects who develop treatment emergent cytopenic abnormalities at 48 weeks. Started Mar 2013; status: completed.
02
Drugs
peginterferon lambda-1a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01754974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01754974.